THERAPEUTIC EFFECTS OF AN INJECTABLE NEW QUINOLONE, PAZUFLOXACIN, AGAINST POLYMICROBIAL INFECTIONS IN THE UTERINE ENDOMETRITIS MODEL

Polymicrobial infections with aerobes and anaerobes are common in fema le genital tract infections. We evaluated the efficacy of an injectabl e new quinolone, pazufloxacin, using a uterine endometritis model. Rat s were infected with a mixed inoculation of Escherichia coli plus Bact eroides fragilis (MIG of pazufloxacin and ceftazidime: E. coli: 0.05 a nd 1.56 mu g/ml, respectively, B. fragilis: 3.13 and 3.13 mu g/ml, res pectively). After inoculating 10(7) cfu/rat of each organism, pazuflox acin or ceftazidime (10 or 20 mg/kg, respectively, i.v., b.i.d., 3 day s) was administered and compared with the nontreated group. The viable cell counts of the uterine corpus and uterine cervix in pazufloxacin- treated and ceftazidime-treated groups were decreased, compared with t he nontreated group. The viable cell counts of the adnexa in the pazuf loxacin-treated group were significantly decreased, compared with the ceftazidime-treated group. These results suggest that pazufloxacin wou ld be useful for the treatment of polymicrobial infections, especially adnexitis.